Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The semaglutide monthly results breakdown and tirzepatide first month results provide benchmarks for comparison
Structure Therapeutics Sector: Oral small molecule GLP-1 receptor agonists for obesity HQ: San Francisco, CA Year Founded: 2016 (as Eccogene
Key Features: Enhanced Potency: IGF-1 LR3 exhibits approximately three times the potency of native IGF-1, attributed to its reduced affinity for IGF-binding proteins, allowing for increased interaction with IGF-1 receptors
We synthesize all our peptides through small-batch production with exact amino-acid sequencing, guaranteeing unparalleled purity and consistency
US$ 20.39
US$ 22.43
US$ 26.87
US$ 20.18
